Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Market Size, Share & Trends Analysis Report by Type (Modality, Reagents, and Service), Application (Drug Discovery & Development, Basic & Translational Research), End Use (Pharma and Biotech Companies), and Region with Growth Forecasts, 2025-2033" has been added to ResearchAndMarkets.com's offering.
The preclinical imaging market, valued at USD 1.1 billion in 2025, is projected to reach USD 1.6 billion by 2033 at a CAGR of 5.6%. This expansion is driven by rising chronic diseases, increased investments in drug development, and soaring demand for non-invasive imaging techniques. Advanced imaging adoption, alongside translational research growth, notably contributes to this trend. Government support, evidenced by initiatives like NIH's funding programs, notably accelerates this expansion by enhancing researchers' access to state-of-the-art tools.
Preclinical imaging methods, including MRI, CT, PET, SPECT, and ultrasound, provide crucial insights into cellular and molecular processes in animal models. For example, a 2025 study demonstrated PET imaging's potential in tracking immune responses in cancer models, offering real-time insights into immune memory formation, essential for evaluating novel treatments before human trials. The strong research infrastructure in developed countries escalates focus on these techniques, enhancing the treatment development landscape.
Chronic and neurodegenerative diseases like Alzheimer's and Parkinson's drive preclinical imaging adoption, particularly in CNS drug discovery. According to the Alzheimer's Association, around 7.2 million Americans, primarily seniors, will have Alzheimer's in 2025. Imaging modalities like PET and SPECT are vital for studying protein aggregation and neuroinflammation, prompting a surge in drug screening programs. AI-driven innovations in imaging processing further propel market progress, exemplified by releases such as Philips CT 3500, which emphasizes high-throughput screening capabilities.
However, market growth faces challenges due to regulations restricting animal testing. Alternative methods like in-vitro tests, computer-based models, and non-invasive imaging technologies are gaining traction, balancing the market dynamics by minimizing ethical concerns and compliance hurdles.
Why should you buy this report?
- Comprehensive Market Analysis: Detailed insights across major regions and segments.
- Competitive Landscape: Explore key players' market presence.
- Future Trends: Understand pivotal trends and drivers shaping the market's future.
- Actionable Recommendations: Utilize insights for new revenue streams and strategic decisions.
This report addresses:
- Market intelligence for effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for staying ahead of the curve
Companies Featured
The leading players profiled in this Preclinical Imaging market report include:
- Cubresa Inc.
- Bruker Corporation
- Revvity (PerkinElmer, Inc)
- FUJIFILM VisualSonics
- Mediso Ltd.
- Rigaku (MILabs B.V.)
- MR Solutions
- Aspect Imaging
- TriFoil Imaging
- Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/cf3mil
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
